Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Uterine Cervical Neoplasms 3Uterine Cervical Dysplasia 2Papillomavirus Infections 2Rheumatic Diseases 1Persistent Infection 1Neoplasms 1HIV Infections 1

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 4Papillomavirus Vaccines 3Vaccines 2human papillomavirus vaccine, L1 type 16, 18 1TachoSil 1Mindfulness 1Human Papillomavirus Recombinant Vaccine nonavalent 1Epinephrine 1Bupivacaine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Uterine Cervical Dysplasia × Vaccines × Clear all
NCT03629886 2024-03-15

Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study

GlaxoSmithKline

Phase 4 Completed
6,051 enrolled 11 charts
Gynecologic

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms

NCT05426148 2022-06-29

Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female

Xiamen Innovax Biotech Co., Ltd

Phase 4 Completed
540 enrolled
Gynecologic

Persistent Infection, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡